DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
HLN logo

Haleon plc Stock Price

LSE:HLN Community·UK£29.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 77 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

HLN Share Price Performance

UK£3.34
-0.23 (-6.42%)
​
UK£4.14
Fair Value
UK£3.34
-0.23 (-6.42%)
19.4% undervalued intrinsic discount
UK£4.14
Fair Value
Price UK£3.34
AnalystConsensusTarget UK£4.14
AnalystLowTarget UK£3.15
AnalystHighTarget UK£5.12
Thu, 4 Sep 25
Fair ValueUK£4.14
Share Pricen/a

HLN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value UK£4.14 19.4% undervalued intrinsic discount

Emerging Markets And Digital Channels Will Transform Global Reach

0users have liked this narrative
0users have commented on this narrative
39users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value UK£3.15 6.0% overvalued intrinsic discount

Rising Regulatory Costs And Shifting Consumer Preferences Will Undermine Performance

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value UK£5.12 34.8% undervalued intrinsic discount

Aging Global Demand And Digital Reach Will Drive Consumer Healthcare

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
HLN logo
Haleon
6.0% overvalued intrinsic discount

Rising Regulatory Costs And Shifting Consumer Preferences Will Undermine Performance

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 1 Jul
Read Narrative
HLN logo
Haleon
34.8% undervalued intrinsic discount

Aging Global Demand And Digital Reach Will Drive Consumer Healthcare

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 10 May
Read Narrative
HLN logo
Haleon
19.4% undervalued intrinsic discount

Emerging Markets And Digital Channels Will Transform Global Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 1 May 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
HLN logo

HLN: Lower Forward P E Assumptions Will Pressure Future Share Price

Fair Value: UK£3.15 6.0% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
HLN logo

HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating

Fair Value: UK£5.12 34.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
HLN logo

Emerging Markets And Digital Channels Will Transform Global Reach

Fair Value: UK£4.14 19.4% undervalued intrinsic discount
39 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with proven track record.

1 Risk
5 Rewards
View Full Analysis

Haleon plc Key Details

UK£11.2b

Revenue

UK£3.8b

Cost of Revenue

UK£7.3b

Gross Profit

UK£5.7b

Other Expenses

UK£1.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.18
65.57%
14.55%
49.2%
View Full Analysis

About HLN

Founded
1715
Employees
24535
CEO
Brian McNamara
WebsiteView website
www.haleon.com

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Recent HLN News & Updates

Recent updates

No updates

Haleon plc Competitors

GSK logo

GSK

Symbol: LSE:GSK
Market cap: UK£70.9b
HIK logo

Hikma Pharmaceuticals

Symbol: LSE:HIK
Market cap: UK£3.2b
HCM logo

HUTCHMED (China)

Symbol: AIM:HCM
Market cap: UK£1.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide